close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.57 +0.64 (+1.31%)
Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
News headline image
Why Novo Nordisk Stock Topped the Market Today ↗
Bullishness slowly seems to be coming back to the beleaguered drugmaker. 
Via The Motley Fool
News headline image
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Why Eli Lilly Stock Popped Today ↗
The GLP-1 weight loss wars have gone global. 
Via The Motley Fool
News headline image
Weighing The Costs: Obesity Drug Users Make Financial Sacrifices As Coverage Tightens ↗
Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs. 
Via Benzinga
News headline image
How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment ↗
Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting treatment options despite competition from Eli Lilly. 
Via Benzinga
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines – NVO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Investors Who Lost Money on Novo Nordisk A/S (NVO) Should Contact Levi &amp; Korsinsky About Pending Class Action - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
The 3 Things That Matter for Viking Therapeutics Now ↗
Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations. 
Via The Motley Fool
News headline image
September 30, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
September 30, 2025 Deadline: Contact Levi &amp; Korsinsky to Join Class Action Suit Against NVO
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Hims & Hers Remains Outside Novo Nordisk's Growing Legal Storm For Now ↗
Novo Nordisk filed more Wegovy lawsuits against smaller U.S. firms, as the FDA sets a compounding deadline. Hims & Hers was not named in the new cases. 
Via Benzinga
Topics Lawsuit
News headline image
UK Government, Eli Lilly Partner To Target Obesity Health Gaps ↗
A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and pharmacy-based services by summer 2026. 
Via Benzinga
News headline image
Best Stock to Buy: Eli Lilly Stock vs. Novo Nordisk Stock ↗
Investors have a tough choice between these two excellent companies. 
Via The Motley Fool
News headline image
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO): A Strong Value Investment with Undervalued Potential ↗
NOVO-NORDISK (NVO) is a top value stock with strong fundamentals, undervalued metrics, high profitability, and steady growth in diabetes & obesity care markets. 
Via Chartmill
News headline image
Novo Nordisk Stock: Buy or Sell? ↗
News from a competitor is increasing enthusiasm for Novo Nordisk stock. 
Via The Motley Fool
News headline image
Is the Market Bullish or Bearish on Novo Nordisk? ↗
 
Via Benzinga
News headline image
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts ↗
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to... 
Via Benzinga
Topics Lawsuit
News headline image
Deadline Alert: Novo Nordisk A/S (NVO) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Shareholders That lost Money on Novo Nordisk A/S (NVO) Should Contact Levi &amp; Korsinsky About Pending Class Action - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Shareholders That lost Money on Novo Nordisk A/S (NVO) Should Contact Levi & Korsinsky About Pending Class Action - NVO
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
4 of the Most Undervalued Stocks in the Market Right Now ↗
They all offer great value right now. 
Via The Motley Fool
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important Deadline in Securities Class Action - NVO
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
2 High-Yield Dividend Stocks You Can Buy With $100 Now and Hold at Least a Decade ↗
These two underappreciated dividend payers offer above-average yields and relatively rapid payout growth. 
Via The Motley Fool
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Trump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli Lilly ↗
Trump’s plan to cover weight loss drugs under Medicaid programs and Medicare Part D plans to could be a major tailwind for LLY and NVO, despite tarrif threats. 
Via MarketBeat
Topics Government World Trade
News headline image
MarketBeat Week in Review – 08/04 - 08/08 ↗
Stocks were higher for the week as investors overlooked tariff uncertainty, but the bulls may get tested by next week's data on inflation and retail sales 
Via MarketBeat
Topics ETFs Economy World Trade
News headline image
Why Hims & Hers Stock Sank This Week ↗
The telehealth platform is growing quickly but is in the middle of a legal battle. 
Via The Motley Fool
Topics Lawsuit
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today